Roche buys GenMark for $1.8 million to challenge test rivals
By Reuters Staff 3 Min Read ZURICH (Reuters) - Roche is filling a testing portfolio gap by buying U.S.-based GenMark Diagnostics in a $1.8 billion deal that the Swiss pharmaceuticals manufacturer said taps one of the fastest-growing diagnostics areas. FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann Basel-based Roche launched a cash offer for GenMark for $24.05 per share, a premium of 43% on GenMark’s Feb. 10 share price, before media deal speculation. The transaction should close in the second quarter. G...